loading page

Prognostic Value of Preoperative Inflammation Markers in Non-Muscle Invasıve Bladder Cancer
  • Hüseyin Alperen Yıldız,
  • Dogan Deger,
  • Guven Aslan
Hüseyin Alperen Yıldız
Malazgirt State Hospital

Corresponding Author:h.alperenyildiz@gmail.com

Author Profile
Dogan Deger
Edirne State Hospital
Author Profile
Guven Aslan
Dokuz Eylül University
Author Profile


Purpose: To investigate the prediction values of the preoperative NLR, LMR, PLR, MPV, RDW for recurrence and progression of patients with non-muscle invasive bladder cancer (NMIBC). Methods: In this prospective study, 94 consecutive patients, newly diagnosed with NMIBC between July 2017 - August 2018 were included. The blood samples were collected from patients before transurethral resection of bladder tumor (TURB) and NLR, LMR, PLR, RDW, MPV values were calculated. The effect of these preoperative inflammatory parameters and other clinicopathological parameters on recurrence and progression rates were evaluated. Kaplan-Meier and multivariate Cox regression analyses were performed to identify significant prognostic variables. Results: The mean follow-up was 11 ± 6.4 months. Recurrence was observed in 35.1% and progression was detected in 7.4% of the patients. Neutrophil-lymphocyte ratio was statistically significantly associated with both recurrence (p = 0.01) and progression (p = 0.035) whereas lymphocyte-monocyte ratio was only associated with recurrence (p = 0.038). In the survival analyses, the relationship between recurrence and LMR was confirmed in both univariate (p = 0.021) and multivariate (p = 0.022) analyses. The relationship between NLR and recurrence was confirmed in univariate analysis (p = 0.019), however in multivariate analysis was found to be statistically insignificant (p = 0.051). Conclusions: Lymphocyte-monocyte ratio might be an easy obtainable, non-invasive and cost-effective method for predicting recurrence of disease in patients with non-muscle invasive bladder cancer.
28 Nov 2020Submitted to International Journal of Clinical Practice
29 Nov 2020Submission Checks Completed
29 Nov 2020Assigned to Editor
03 Dec 2020Reviewer(s) Assigned
19 Dec 2020Review(s) Completed, Editorial Evaluation Pending
17 Feb 20211st Revision Received
18 Feb 2021Submission Checks Completed
18 Feb 2021Assigned to Editor
18 Feb 2021Reviewer(s) Assigned
22 Feb 2021Review(s) Completed, Editorial Evaluation Pending
24 Feb 2021Editorial Decision: Accept